|
|
News Breaks | | | | November 28, 2012 | | 05:55 EDT |  | NVO, NVO, NVO, DNA, DNA, DNA, ARRY, ARRY, ARRY, CBST, CBST, CBST, SHPG, SHPG, SHPG, LLY, LLY, LLY, JNJ, JNJ, JNJ, PFE, PFE, PFE, AGEN, AGEN, AGEN, CYTK, CYTK, CYTK, ASTM, ASTM, ASTM | Windhover to host a conference
Therapeutic Area Partnerships is being held in Boston on November 28-30. | |
|
News For ASTM;CYTK;AGEN;PFE;JNJ;LLY;SHPG;CBST;ARRY;DNA;NVO From The Last 14 Days Check below for free stories on ASTM;CYTK;AGEN;PFE;JNJ;LLY;SHPG;CBST;ARRY;DNA;NVO the last two weeks. |
|
|
| June 18, 2013 | | 19:07 EDT |  | CYTK | On The Fly: After Hours Movers
 Subscribe for More Information | | | 17:25 EDT | | CYTK | Amgen reports 7.58% stake in Cytokinetics
Subscribe for More Information | | | 15:15 EDT | | NVO | Novo Nordisk says court rules against company in patent litigation
Subscribe for More Information | | | 13:30 EDT |  | AGEN | Agenus initiated with a Buy at Maxim
Subscribe for More Information | | | 10:17 EDT |  | LLY | Lilly puts active on FDA says investigating two deaths after Zyprexa injections
Subscribe for More Information | | | 10:12 EDT | | LLY | FDA investigating two deaths of patients taking Lilly's Zyprexa
The FDA said in a safety announcement on its website that it is investigating two unexplained deaths in patients who received an intramuscular injection of the antipsychotic drug Zyprexa. The patients died 3-4 days after receiving an appropriate dose of the drug, well after the 3-hour post-injection monitoring period required under the Zyprexa Risk Evaluation and Mitigation Strategy, the agency said. Both patients were found to have very high olanzapine blood levels after death. Eli Lilly is the maker of Zyprexa. | | | 09:38 EDT | | PFE | Active equity option families trading on open
Active equity option families trading on open according to Track Data: AAPL NFLX GOOG PFE TSLA MGM | | | 07:34 EDT |  | JNJ | Medivation pullback a buying opportunity, says JPMorgan
Subscribe for More Information | | | 07:22 EDT | | SHPG | Citigroup to host a conference
Subscribe for More Information | | | June 17, 2013 | | 16:20 EDT |  | JNJ | On The Fly: Closing Wrap
Stocks on Wall Street were higher following a session dominated by speculation over what is next for the Federal Reserve. The averages trimmed their gains after an article by the Financial Times suggested the Fed would signal a tapering of its pace of asset purchases at its Wednesday press conference. The upward trend resumed after the article's author said the report was based on opinion and that, "The Fed does not leak anything to any journalist to steer markets - especially during blackout." ECONOMIC EVENTS: In the U.S., the New York Fed Empire State Survey for June came in at 7.40, versus expectations for a 0 reading. The NAHB housing market confidence index for June rose to 52, versus the forecast for a more modest climb to 45 from its prior 44 reading. In Europe, Germany's Bundesbank said economic indicators for April pointed to robust growth in the second quarter and business sentiment improved in May, though warned of signs that growth in Europe's largest economy would slow over the summer. COMPANY NEWS: Netflix (NFLX) and DreamWorks (DWA) both climbed after announcing a major content deal. Under the agreement, DreamWorks will provide over 300 hours of content to Netflix, which the TV and movie service expects to start broadcasting next year. After the announcement, Netflix rose $15.24, or 7.12%, to $229.23, while DreamWorks added 93c, or 4.08%, to $23.74. MAJOR MOVERS: Among the notable gainers was Kandi Technologies (KNDI), up $1.53, or 24.4%, to $7.80 after saying it will deploy 5K-10K pure electric vehicles in China within the first year of launch. Also higher were shares of ViroPharma (VPHM), up $1.71, or 6.3%, to $28.87 after Reuters said the company has attracted takeover interest, though the company is not pursuing a sale. Among the noteworthy losers was Terex (TEX), down $2.45, or 7.72%, to $29.29 after the company lowered it fiscal year earnings view. Also lower was Medivation (MDVN), down $3.45, or 6.78%, to $47.41 after Johnson & Johnson (JNJ) acquired the company's competitor, privately held Aragon Pharmaceuticals. INDICES: The Dow was up 109.67, or 0.73%, to 15,179.85; the Nasdaq was up 28.57, or 0.83%, to 3,452.13; and the S&P 500 was up 12.31, or 0.76%, to 1,639.04. | | | | 16:00 EDT | | PFE | Options Update; June 17, 2013
Subscribe for More Information | | | 12:29 EDT | | JNJ | On The Fly: Midday Wrap
Subscribe for More Information | | | 12:28 EDT | | JNJ | Medivation retreats after J&J beefs up prostate cancer slate
Subscribe for More Information | | | 12:08 EDT | | JNJ | J&J deal not negative for Medivation, says Citigroup
Subscribe for More Information | | | 11:55 EDT | | SHPG | High option volume stocks: SPHG CSIQ TS GAME CRZO
Subscribe for More Information | | | 11:34 EDT | | LLY | Eli Lilly: LIVALO 4mg has neutral effects on fasting serum glucose levels
Kowa Pharmaceuticals America and Eli Lilly and Company announced results of a pre-specified safety analysis from the INTREPID (HIV-infected patieNts and TREatment with PItavastatin vs. pravastatin for Dyslipidemia) trial evaluating the effect of LIVALO 4 mg compared with pravastatin 40 mg on changes in levels of blood glucose and glycated hemoglobin in HIV-infected adults with dyslipidemia. INTREPID was a Phase 4, multicenter, 12-week randomized superiority study followed by a 40-week safety extension study comparing the lipid-lowering effects of pitavastatin 4 mg and pravastatin 40 mg in adults with HIV infection and dyslipidemia. The results of this pre-specified safety analysis, presented yesterday at the Endocrine Society's 95th Annual Meeting & Expo in San Francisco, CA, showed neutral effects of pitavastatin 4 mg and pravastatin 40 mg on fasting serum glucose and HbA1c levels over 12 weeks. | | | 11:17 EDT | | LLY | Eli Lilly to host conference call
Subscribe for More Information | | | 10:10 EDT |  | NVO | On The Fly: Analyst Downgrade Summary
Subscribe for More Information | | | 08:36 EDT | | PFE | InSite Vision to join Merck, Pfizer patent suit against Mylan
InSite Vision (INSV) announced that it will join Merck (MRK) and Pfizer (PFE) in filing a patent infringement lawsuit against Mylan Pharmaceuticals (MYL). Mylan recently filed an Abbreviated New Drug Application with the U.S. Food and Drug Administration seeking to market a generic version of AzaSite before expiration of the patents covering AzaSite and its use. AzaSite is marketed by Merck in the U.S. On May 26, 2011, InSite and Merck filed a similar patent infringement lawsuit against Sandoz. A trial date for the Sandoz ANDA suit has been set for July 11, 2013. The companies have agreed that Merck will take the lead in prosecuting both lawsuits. Each company will be responsible for their own legal costs, with InSite assuming a monitoring role, the company said. | | | 08:04 EDT | | JNJ | Johnson & Johnson agrees to acquire Aragon Pharmaceuticals
Johnson & Johnson announced a definitive agreement to acquire Aragon Pharmaceuticals, a privately-held, pharmaceutical discovery and development company focused on drugs to treat hormonally-driven cancers. The acquisition includes Aragon's androgen receptor antagonist program. Aragon's lead product candidate is a second generation androgen receptor signaling inhibitor, ARN-509, in Phase 2 development for castration resistant prostate cancer. Under the terms of the agreement, Johnson & Johnson will make an upfront cash payment of $650M, plus additional contingent payments of up to $350M based on reaching predetermined milestones. The transaction is expected to close in the third quarter of 2013. | | |
|
|
|
|
|
|
